Dissecting the Evolution of Immunotherapy in Endometrial Cancer From ESMO 2025

Panelists discuss how molecular testing enables precise categorization of endometrial cancer into biologically distinct subtypes that guide prognosis, therapy selection, and future research direction.

Panelists discuss how patient and disease characteristics guide the selection of frontline immunotherapy regimens in recurrent or metastatic endometrial cancer.

Panelists discuss how survival data from the RUBY study highlight the benefits of dostarlimab plus chemotherapy in pMMR/MSS and older patient populations with advanced endometrial cancer.

Panelists discuss how careful management of adverse events and quality-of-life factors optimizes the safe use of dostarlimab plus chemotherapy in endometrial cancer.

Panelists discuss how evolving immunotherapy combinations and NCCN guidelines shape frontline treatment selection for advanced or recurrent endometrial cancer.

Panelists discuss how emerging therapies and biomarker-driven research are shaping the next wave of innovation in endometrial cancer treatment.

Panelists discuss how addressing molecular, clinical, and access-related gaps remains essential for advancing endometrial cancer research and care.